Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis

Purpose. Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. Methods. CCK8 assay was used to measure cell viability rate of K562/ADR. Int...

Full description

Bibliographic Details
Main Authors: Wenjing Wang, Shubin Niu, Luxin Qiao, Feili Wei, Jiming Yin, Shanshan Wang, Yabo Ouyang, Dexi Chen
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2019/8727935
id doaj-177dee0ff5c145c19975eda7ae0c3c92
record_format Article
spelling doaj-177dee0ff5c145c19975eda7ae0c3c922020-11-24T21:59:19ZengHindawi LimitedBioMed Research International2314-61332314-61412019-01-01201910.1155/2019/87279358727935Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent ApoptosisWenjing Wang0Shubin Niu1Luxin Qiao2Feili Wei3Jiming Yin4Shanshan Wang5Yabo Ouyang6Dexi Chen7Capital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaSchool of biomedicine, Beijing City University, No. 6 Huanghoudian Road Haidian District, Beijing, 100094, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaCapital Medical University Affiliated Beijing You An Hospital, Beijing, 100069, ChinaPurpose. Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. Methods. CCK8 assay was used to measure cell viability rate of K562/ADR. Intracellular reactive oxygen species (ROS) generation, cell cycle distribution, cell apoptosis were measured with flow cytometry, respectively. Proteins related to apoptosis were measured by Western blot. Intracellular Adriamycin accumulation was observed by confocal microscopy and measured by flow cytometry. Results. In vitro study showed intracellular Adriamycin accumulation was remarkably increased by UA. Cell viability treated with Adr (4 μM) was decreased from 89.8%  ± 4.7 to 32%  ± 8.9 by combined with UA (4 μM). Adr-induced apoptosis and G1/G0 phase cell cycle arrest were remarkably increased by UA, as well as, intracellular ROS level. However, MDR reversing activity of UA was inhibited by N-acetyl cysteine (NAC), a ROS scavenger. Conclusion. These data provide compelling evidence that UA is a promising agent against MDR in leukemia cell line and suggest a promising therapeutic approach for leukemia.http://dx.doi.org/10.1155/2019/8727935
collection DOAJ
language English
format Article
sources DOAJ
author Wenjing Wang
Shubin Niu
Luxin Qiao
Feili Wei
Jiming Yin
Shanshan Wang
Yabo Ouyang
Dexi Chen
spellingShingle Wenjing Wang
Shubin Niu
Luxin Qiao
Feili Wei
Jiming Yin
Shanshan Wang
Yabo Ouyang
Dexi Chen
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
BioMed Research International
author_facet Wenjing Wang
Shubin Niu
Luxin Qiao
Feili Wei
Jiming Yin
Shanshan Wang
Yabo Ouyang
Dexi Chen
author_sort Wenjing Wang
title Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_short Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_full Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_fullStr Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_full_unstemmed Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
title_sort usnea acid as multidrug resistance (mdr) reversing agent against human chronic myelogenous leukemia k562/adr cells via an ros dependent apoptosis
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2019-01-01
description Purpose. Multidrug resistance (MDR) is a major obstacle in chemotherapy of leukemia treatments. In this paper, we investigated Usnea Acid (UA) as MDR reversal agent on hematologic K562/ADR cells via ROS dependent apoptosis. Methods. CCK8 assay was used to measure cell viability rate of K562/ADR. Intracellular reactive oxygen species (ROS) generation, cell cycle distribution, cell apoptosis were measured with flow cytometry, respectively. Proteins related to apoptosis were measured by Western blot. Intracellular Adriamycin accumulation was observed by confocal microscopy and measured by flow cytometry. Results. In vitro study showed intracellular Adriamycin accumulation was remarkably increased by UA. Cell viability treated with Adr (4 μM) was decreased from 89.8%  ± 4.7 to 32%  ± 8.9 by combined with UA (4 μM). Adr-induced apoptosis and G1/G0 phase cell cycle arrest were remarkably increased by UA, as well as, intracellular ROS level. However, MDR reversing activity of UA was inhibited by N-acetyl cysteine (NAC), a ROS scavenger. Conclusion. These data provide compelling evidence that UA is a promising agent against MDR in leukemia cell line and suggest a promising therapeutic approach for leukemia.
url http://dx.doi.org/10.1155/2019/8727935
work_keys_str_mv AT wenjingwang usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT shubinniu usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT luxinqiao usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT feiliwei usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT jimingyin usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT shanshanwang usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT yaboouyang usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
AT dexichen usneaacidasmultidrugresistancemdrreversingagentagainsthumanchronicmyelogenousleukemiak562adrcellsviaanrosdependentapoptosis
_version_ 1725847799941038080